个人简介：

Dr. Junning Lee, Founder and CEO of Lexenpharm, has over 28 years of experience in the pharmaceutical and biotech industries. Dr. Lee was Senior Vice President of Technical Operations at Theravance Biopharma and Senior Vice President of Technical Operations for Theravance Inc. During Dr. Lee’s tenure with Theravance, he was responsible for pharmaceutical technology development, manufacturing, CTM and commercial productions, and supply chain management. Prior to Theravance, Dr. Lee spent more than 11 years with Schering-Plough Research Institute. During his career, Dr. Lee managed over 35 clinical and commercial projects during development and manufacturing phases. He holds over 40 US patents of discovery and manufacturing technologies of novel medicines.Dr. Lee obtained his Ph.D. in Chemistry from Boston University and a post-doctoral research fellowship in Bioorganic Chemistry from Oregon State University. He received his Bachelors of Science in Pharmacy from China Pharmaceutical University.

Dr. Lee is the formal president of SAPA, and a member of Bayhelix, CABS & New Drug Founder Club. He is the current president of the Biopharmaceutical Industrial Union.

公司简介：

Lexenpharm, headquartered in the one of China's foremost industrial parks in Suzhou, Jiangsu Province, is a vanguard in pharmaceutical research and manufacturing. The company, founded by Dr. Junning Lee, leverages the extensive and diverse experience of its founding team, encompassing a broad spectrum of pharmaceutical research and production expertise. Lexenpharm stands as a testament to pioneering innovation in the pursuit of excellence within the pharmaceutical landscape.

Lexenpharm focuses on producing first-to-market generic medicines that treat disease affecting large populations. The company also actively engages in research projects of innovative products that provide a better therapeutic solution to prevalent indications. 

Communication, Capability, Capacity, Creativity, Commitment, Cost, Compliance.